CG Oncology Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021
Revenue	0.2	0.19	10.36
Revenue Growth (YoY)	6.81%	-98.16%	-
Gross Profit	0.2	0.19	10.36
Selling, General & Admin	9.9	6.41	4.65
Research & Development	45.75	29.03	18.32
Operating Expenses	55.65	35.44	22.96
Operating Income	-55.45	-35.25	-12.61
Interest Expense / Income	-6.9	0	0.45
Other Expense / Income	0.06	0.2	-0.22
Pretax Income	-48.61	-35.44	-12.84
Net Income	-48.61	-35.44	-12.84
Preferred Dividends	19.19	8.35	5.54
Net Income Common	-67.8	-43.79	-18.38
Shares Outstanding (Basic)	4	4	4
Shares Outstanding (Diluted)	4	4	4
Shares Change	15.77%	2.47%	-
EPS (Basic)	-15.65	-11.71	-5.04
EPS (Diluted)	-15.65	-11.71	-5.04
Free Cash Flow	-45.68	-29.82	-13.75
Free Cash Flow Per Share	-10.55	-7.97	-3.77
Gross Margin	100.00%	100.00%	100.00%
Operating Margin	-27180.88%	-18453.40%	-121.70%
Profit Margin	-33234.31%	-22925.65%	-177.48%
Free Cash Flow Margin	-22391.67%	-15611.52%	-132.76%
EBITDA	-55.48	-35.41	-12.38
EBITDA Margin	-27197.06%	-18539.27%	-119.47%
Depreciation & Amortization	0.03	0.03	0.01
EBIT	-55.51	-35.44	-12.39
EBIT Margin	-27211.27%	-18556.02%	-119.60%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).